Therapeutic potential of mitotic kinesin inhibitors in cancer

Bibliography

• Miki H, Okada Y, Hirokawa N. Analysis of the kinesin superfamily: insights into structure and function. Trends Cell Biol 2005;15:467-76
   PubMed Web of Science ®Google Scholar
• Dagenbach EM, Endow SA. A new kinesin tree. J Cell Sci 2004;117:3-7
   PubMed Web of Science ®Google Scholar
• Wittmann T, Hyman A, Desai A. The spindle: a dynamic assembly of microtubules and motors. Nat Cell Biol 2001;3:E28-34
   PubMed Web of Science ®Google Scholar
• Heald R. Motor function in the mitotic spindle. Cell 2000;102:399-402
   PubMed Web of Science ®Google Scholar
• Sharp DJ, Rogers GC, Scholey JM. Microtubule motors in mitosis. Nature 2000;407:41-7
   PubMed Web of Science ®Google Scholar
• Belmont LD. Mitotic kinesins as targets for anticancer therapy. AACR Educ Book 2005;173-7
   Google Scholar
• Schmidt M, Bastians H. Mitotic drug targets and the development of novel anti-mitotic anticancer drugs. Drug Resist Update 2007;10:162-81
   PubMed Web of Science ®Google Scholar
• Sawin KE, Leguellec K, Philippe M, Mitchison TJ. Mitotic spindle organization by a plus-end-directed microtubule motor. Nature 1992;359:540-3
   PubMed Web of Science ®Google Scholar
• Kashina AS, Baskin RJ, Cole DG, et al. A bipolar kinesin. Nature 1996;379:270-2
   PubMed Web of Science ®Google Scholar
• Blangy A, Lane HA, D'Herin P, et al. Phosphorylation by p34cdc2 regulates spindle association of human Eg5, a kinesin-related motor essential for bipolar spindle formation in vivo. Cell 1995;83:1159-69
   PubMed Web of Science ®Google Scholar
• Kapitein LC, Peterman EJ, Kwok BH, et al. The bipolar mitotic kinesin Eg5 moves on both microtubules that it crosslinks. Nature 2005;435:114-8
   PubMed Web of Science ®Google Scholar
• Tao W, South VJ, Zhang Y, et al. Induction of apoptosis by an inhibitor of the mitotic kinesin KSP requires both activation of the spindle assembly checkpoint and mitotic slippage. Cancer Cell 2005;8:49-59
   PubMed Web of Science ®Google Scholar
• Weaver BA, Cleveland DW. Decoding the links between mitosis, cancer, and chemotherapy: the mitotic checkpoint, adaptation, and cell death. Cancer Cell 2005;8:7-12
   PubMed Web of Science ®Google Scholar
• Tao W, South VJ, Diehl RE, et al. An inhibitor of the kinesin spindle protein activates the intrinsic apoptotic pathway independently of p53 and de novo protein synthesis. Mol Cell Biol 2007;27:689-98
   PubMed Web of Science ®Google Scholar
• Kapoor TM, Mayer TU, Coughlin ML, Mitchison TJ. Probing spindle assembly mechanisms with monastrol, a small molecule inhibitor of the mitotic kinesin, Eg5. J Cell Biol 2000;150:975-88
   PubMed Web of Science ®Google Scholar
• Yen TJ, Compton DA, Wise D, et al. CENP-E, a novel human centromere-associated protein required for progression from metaphase to anaphase. EMBO J 1991;10:1245-54
   PubMed Web of Science ®Google Scholar
• Yen TJ, Li G, Schaar BT, et al. CENP-E is a putative kinetochore motor that accumulates just before mitosis. Nature 1992;359:536-9
   PubMed Web of Science ®Google Scholar
• Wood KW, Sakowicz R, Goldstein LS, Cleveland DW. CENP-E is a plus end-directed kinetochore motor required for metaphase chromosome alignment. Cell 1997;91:357-66
   PubMed Web of Science ®Google Scholar
• Thrower DA, Jordan MA, Wilson L. Modulation of CENP-E organization at kinetochores by spindle microtubule attachment. Cell Motil Cytoskel 1996;35:121-33
   PubMed Web of Science ®Google Scholar
• Deluca JG, Newton CN, Himes RH, et al. Purification and characterization of native conventional kinesin, HSET, and CENP-E from mitotic HeLa cells. J Biol Chem 2001;276:28014-21
   PubMed Web of Science ®Google Scholar
• Garcia-Saez I, Yen T, Wade RH, Kozielski F. Crystal structure of the motor domain of the human kinetochore protein CENP-E. J Mol Biol 2004;340:1107-16
   PubMed Web of Science ®Google Scholar
• Neumann I, Garcia-Saez S, Debonis R, et al. Human kinetochore-associated kinesin CENP-E visualized at 17 Å resolution bound to microtubules. J Mol Biol 2006;362:203-11
   PubMed Web of Science ®Google Scholar
• Brown KD, Wood KW, Cleveland DW. The kinesin-like protein CENP-E is kinetochoreassociated throughout poleward chromosome segregation during anaphase-A. J Cell Sci 1996;109:961-9
   PubMed Web of Science ®Google Scholar
• Yao X, Abrieu A, Zheng Y, et al. CENP-E forms a link between attachment of spindle microtubules to kinetochores and the mitotic checkpoint. Nat Cell Biol 2000;2:484-91
   PubMed Web of Science ®Google Scholar
• Putkey FR, Cramer T, Morphew MK, et al. Unstable kinetochore-microtubule capture and chromosomal instability following deletion of CENP-E. Dev Cell 2002;3:351-65
   PubMed Web of Science ®Google Scholar
• Abrieu A, Kahana JA, Wood KW, Cleveland DW. CENP-E as an essential component of the mitotic checkpoint in vitro. Cell 2000;102:817-26
   PubMed Web of Science ®Google Scholar
• Mao Y, Abrieu A, Cleveland DW. Activating and silencing the mitotic checkpoint through CENP-E-dependent activation/inactivation of BubR1. Cell 2003;114:87-98
   PubMed Web of Science ®Google Scholar
• Tanudji M, Shoemaker J, L'Italien L, et al. Gene silencing of CENP-E by small interfering RNA in HeLa cells leads to missegregation of chromosomes after a mitotic delay. Mol Biol Cell 2004;15:3771-81
   PubMed Web of Science ®Google Scholar
• Mayer TU, Kapoor TM, Haggarty SJ, et al. Small molecule inhibitor of mitotic spindle bipolarity identified in a phenotype-based screen. Science 1999;286:971-4
   PubMed Web of Science ®Google Scholar
• Yan Y, Sardana V, Xu B, et al. Inhibition of a mitotic motor protein: where, how, and conformational consequences. J Mol Biol 2004;335:547-54
   PubMed Web of Science ®Google Scholar
• Debonis S, Simorre J-P, Crevel I, et al. Interaction of the mitotic inhibitor monastrol with human kinesin Eg5. Biochemistry 2003;42:338-49
   PubMed Web of Science ®Google Scholar
• Maliga Z, Kapoor TM, Mitchison TJ. Evidence that monastrol is an allosteric inhibitor of the mitotic kinesin Eg5. Chem Biol 2002;9:989-96
   PubMed Web of Science ®Google Scholar
• Bergnes G, Brejc K, Belmont L. Mitotic kinesins: prospects for antimitotic drug discovery. Curr Top Med Chem 2005;5:127-45
   PubMed Web of Science ®Google Scholar
• Duhl DM, Renhowe PA. Inhibitors of kinesin motor proteins: research and clinical progress. Curr Opin Drug Discov Dev 2005;8:431-6
   PubMed Web of Science ®Google Scholar
• Hotta K, Ueoka H. New cytotoxic agents: a review of the literature. Crit Rev Oncol Hematol 2005;55:45-65
   PubMed Web of Science ®Google Scholar
• Zhang B, Senator D, Wilson CJ, Ng SC. Development of a high-throughput robotic fluorescence-based assay for HsEg5 inhibitor screening. Anal Biochem 2005;345:326-35
   PubMed Web of Science ®Google Scholar
• Davis DA, Sarkar SH, Hussain M, et al. Increased therapeutic potential of an experimental anti-mitotic inhibitor SB715992 by genistein in PC-3 human prostate cancer cell line. BMC Cancer 2006;6:22-32
   PubMedGoogle Scholar
• Chu Q, Holen KD, Rowinsky EK, et al. A phase I study to determine the safety and pharmacokinetics of IV administered SB-715992, a novel kinesin spindle protein (KSP) inhibitor, in patients (pts) with solid tumors. Proc Am Soc Clin Oncol 2003;22:[Abstract 525]
   Google Scholar
• Rodon J, Till E, Patnaik A, et al. Phase I study of ispinesib (SB-715992), a kinesin spindle protein inhibitor, in combination with capecitabine in patients with advanced solid tumors. Eur J Cancer 2006;4:[Abstract 640]
   Google Scholar
• Tang P, Siu LL, Chen EX, et al. A phase II study of ispinesib in patients (pts) with recurrent and/or metastatic head and neck squamous cell carcinoma (RMHNSC). Ann Oncol 2006;17(S):[Abstract 600P]
   Google Scholar
• Jackson JR, Gilmartin A, Dhanak D, et al. A second generation KSP inhibitor, SB-743921, is a highly potent and active therapeutic in preclinical models of cancer. First Mol Diagn Cancer Ther Dev 2006;[Abstract B11]
   Google Scholar
• Belmont LD, Wood KW, Sutton D, et al. Sequence dependent anti-tumor activity of bortezomib and the KSP inhibitor, SB743921, in a solid tumor xenograft model. Eur J Cancer 2006;4:[Abstract 378]
   Google Scholar
• Holen KD, Belani CP, Wilding G, et al. Phase I study to determine tolerability and pharmacokinetics (PK) of SB-743921, a novel kinesin spindle protein (KSP) inhibitor. J Clin Oncol 2006;24:[Abstract 2000]
   Google Scholar
• A Phase I-II study to determine the safety and pharmacokinetics of intravenous administration of SB-743921 on days 1 and 15 of a 28 day cycle in patients with non-Hodgkin's lymphoma (NCT00343564). ClinicalTrials.gov. 21 June 2006. Available at: http://clinicaltrials.gov/show/NCT00343564 [Last accessed 14 November 2007]
   Google Scholar
• Stein MN, Rubin EH, Scott PD, et al. Phase I clinical and pharmacokinetic (PK) trial of the kinesin spindle protein (KSP) inhibitor MK-0731 in cancer patients. J Clin Oncol 2006;24:[Abstract 2001]
   Google Scholar
• Stein MN, Tan A, Taber K, et al. Phase I clinical and pharmacokinetic (PK) trial of the kinesin spindle protein (KSP) inhibitor MK-0731 in patients with solid tumors. J Clin Oncol 2007;25:[Abstract 2548]
   Google Scholar
• A study of MK0731 in patients with advanced solid tumors (NCT104364). 25 February 2005. ClinicalTrials.gov. Available at: http://clinicaltrials.gov/ct2/show/NCT00104364?term=MK0731&rank=1 [Last accessed 14 November 2007]
   Google Scholar
• Array BioPharma reports full-year 2007 R&D highlights. Array Biopharma. press release. 6 August 2007. ClinicalTrials.gov. Available at: http://investor.arraybiopharma.com/phoenix.zhtml?c=123810&p=irol-newsArticle&ID=1037137&highlight [Last accessed 14 November 2007]
   Google Scholar
• Tolerability study of investigational agent, ARRY-520, in subjects with cancer (NCT00462358). 18 April 2007. ClinicalTrials.gov. Available at: http://clinicaltrials.gov/ct2/show/NCT00462358?term=ARRY-520&rank=1 [Last accessed 14 November 2007]
   Google Scholar
• Merck KGaA reports Q3 2007 R&D highlights. Merck KGaA press release. 24 October 2007. Available at: http://www.merck.de/servlet/PB/show/1755050/Merck_Q3_2007_handout_portfolio_review.pdf [Last accessed 14 November 2007]
   Google Scholar
• Lad L, Luo L, Wood K, et al. Detailed biochemical analysis of the CENP-E inhibitor GSK923295A. Proc Am Assoc Cancer Res 2007;48:[Abstract 3179]
   Google Scholar
• Sutton D, Diamond M, Faucette L, et al. GSK923295A, a potent and selective CENP-E inhibitor, has broad spectrum activity against human tumor xenografts in nude mice. Proc Am Assoc Cancer Res 2007;48:[Abstract 1522]
   Google Scholar
• Phase I study to assess the safety, pharmacokinetics & pharmacodynamics of GSK923295 in subjects with refractory cancer (NCT00504790). ClinicalTrials.gov. 18 July 2007. Available at: http://clinicaltrials.gov/ct2/show/NCT00504790?term=GSK923295&rank=1 [Last accessed 14 November 2007]
   Google Scholar
• Coleman PJ, Fraley ME. Inhibitors of the mitotic kinesin spindle protein. Expert Opin Ther Patents 2004;14:1659-67
   Web of Science ®Google Scholar
• Jiang C, You Q, Li Z, Guo Q. Kinesin spindle protein inhibitors as anticancer agents. Expert Opin Ther Patents 2006;16:1517-32
   Web of Science ®Google Scholar
• Commissariat Á L′énergie Atomique. WO2006097617; 2006
   Google Scholar
• Garcia-Saez I, Debonis S, Lopez R, et al. Structure of human Eg5 in complex with a new monastrol-based inhibitor bound in the R configuration. J Biol Chem 2007;282:9740-7
   PubMed Web of Science ®Google Scholar
• Leipzig University/Max-Planck Institute. WO2006048308; 2006
   Google Scholar
• Gartner M, Sunder-Plassmann N, Seiler J, et al. Development and biological evaluation of potent and specific inhibitors of mitotic kinesin Eg5. Chem Biochem 2005;6:1173-7
   Google Scholar
• Sarli V, Huemmer S, Sunder-Plassmann N, et al. Synthesis and biological evaluation of novel Eg5 inhibitors. Chem Biochem 2005;6:2005-13
   Google Scholar
• Harvard University. WO2006074293; 2006
   Google Scholar
• Biginelli P. Ueber aldehyduramide des acetessigäthers. Ber 1891;24:1317-9
   Google Scholar
• Dondoni A, Massi A, Sabbatini S. Improved synthesis and preparative scale resolution of racemic monastrol. Tetrahedron Lett 2002;43:5913-6
   Web of Science ®Google Scholar
• Huang Y, Yang F, Zhu C. Highly enantioseletive Biginelli reaction using a new chiral ytterbium catalyst: asymmetric synthesis of dihydropyrimidines. J Am Chem Soc 2005;127:16386-7
   PubMed Web of Science ®Google Scholar
• Chen XH, Xu XY, Liu H, et al. Highly enantioselective organocatalytic Biginelli reaction. J Am Chem Soc 2006;128:14802-3
   PubMed Web of Science ®Google Scholar
• Klein E, Debonis S, Thiede B, et al. New chemical tools for investigating human mitotic kinesin Eg5. Bioorg Med Chem 2007;15:6474-88
   PubMed Web of Science ®Google Scholar
• Cytokinetics. WO2004100873; 2004
   Google Scholar
• Cytokinetics. WO2004103282; 2004
   Google Scholar
• Cytokinetics. WO2005013888; 2005
   Google Scholar
• Cytokinetics. WO2004091547; 2004
   Google Scholar
• Cytokinetics. WO2005061460; 2005
   Google Scholar
• Cytokinetics. WO2005042697; 2005
   Google Scholar
• Cytokinetics. WO2007067752; 2007
   Google Scholar
• Chiron. WO2004111058; 2004
   Google Scholar
• Chiron. WO2004113335; 2004
   Google Scholar
• Chiron. WO2005100357; 2005
   Google Scholar
• Cytokinetics. WO2004064741; 2004
   Google Scholar
• Chiron. WO2006002236; 2006
   Google Scholar
• Chiron. WO2006049835; 2006
   Google Scholar
• Takeda WO2006060737; 2006
   Google Scholar
• AstraZeneca. WO2006018627; 2006
   Google Scholar
• AstraZeneca. WO2006008523; 2006
   Google Scholar
• AstraZeneca. WO2006018628; 2006
   Google Scholar
• Sakowicz R, Finer JT, Beraud C, et al. Antitumor activity of a kinesin inhibitor. Cancer Res 2004;64:3276-80
   PubMed Web of Science ®Google Scholar
• Merck KGaA. WO2006097176; 2006
   Google Scholar
• BMS. WO2004106492; 2004
   Google Scholar
• AstraZeneca. WO2004078758; 2004
   Google Scholar
• BMS. WO2005077920; 2005
   Google Scholar
• BMS. WO2003099286; 2003
   Google Scholar
• Kim KS, Lu S-F, Cornelius LA, et al. Synthesis and SAR of pyrrolotriazine-4-one based Eg5 inhibitors. Bioorg Med Chem Lett 2006;16:3937-42
   PubMed Web of Science ®Google Scholar
• Merck & Co. WO2005061518; 2005
   Google Scholar
• Merck & Co. WO2006078598; 2006
   Google Scholar
• Merck & Co. WO2006078575; 2006
   Google Scholar
• Merck & Co. WO2006078574; 2006
   Google Scholar
• AstraZeneca. WO2005041888; 2005
   Google Scholar
• Cytokinetics. WO2004009036; 2004
   Google Scholar
• Cytokinetics/GSK. WO2004055008; 2004
   Google Scholar
• Merck & Co. WO2003039460; 2003
   Google Scholar
• Merck KGaA. WO2006125555; 2006
   Google Scholar
• Chiron. WO2005051922; 2005
   Google Scholar
• Chiron. WO2007021794; 2007
   Google Scholar
• Cox CD, Breslin MJ, Mariano BJ, et al. Kinesin spindle protein (KSP) inhibitors. Part 1: the discovery of 3,5-diaryl-4,5-dihydropyrazoles as potent and selective inhibitors of the mitotic kinesin KSP. Bioorg Med Chem Lett 2005;15:2041-5
   PubMed Web of Science ®Google Scholar
• Fraley ME, Garbaccio RM, Arrington KL, et al. Kinesin spindle protein (KSP) inhibitors. Part 2: the design, synthesis, and characterization of 2,4-diaryl-2,5-dihydropyrrole inhibitors of the mitotic kinesin KSP. Bioorg Med Chem Lett 2006;16:1775-9
   PubMed Web of Science ®Google Scholar
• Garbaccio RM, Fraley ME, Tasber ES, et al. Kinesin spindle protein (KSP) inhibitors. Part 3: synthesis and evaluation of phenolic 2,4-diaryl-2,5-dihydropyrroles with reduced hERG binding and employment of a phosphate prodrug strategy for aqueous solubility. Bioorg Med Chem Lett 2006;16:1780-3
   PubMed Web of Science ®Google Scholar
• Cox CD, Torrent M, Breslin MJ, et al. Kinesin spindle protein (KSP) inhibitors. Part 4: structure-based design of 5-alkylamino-3,5-diaryl-4,5-dihydropyrazoles as potent, water-soluble inhibitors of the mitotic kinesin KSP. Bioorg Med Chem Lett 2006;16:3175-9
   PubMed Web of Science ®Google Scholar
• Cox CD, Breslin MJ, Whitman DB, et al. Kinesin spindle protein (KSP) inhibitors. Part 5: discovery of 2-propylamino-2,4-diaryl-2,5-dihydropyrroles as potent, water-soluble KSP inhibitors, and modulation of their basicity by β-fluorination to overcome cellular efflux by P-glycoprotein. Bioorg Med Chem Lett 2007;17:2697-702
   PubMed Web of Science ®Google Scholar
• Coleman PJ, Schreier JD, Cox CD, et al. Kinesin spindle protein (KSP) inhibitors. Part 6:design and synthesis of 3,5-diaryl-4,5-dihydropyrazole amides as potent inhibitors of the mitotic kinesin KSP. Bioorg Med Chem Lett 2007;17:5390-5
   PubMed Web of Science ®Google Scholar
• Merck & Co. WO2006110390; 2006
   Google Scholar
• Merck & Co. WO2006101761; 2006
   Google Scholar
• Merck & Co. WO2006007496; 2006
   Google Scholar
• Merck & Co. WO2005017190; 2005
   Google Scholar
• Merck & Co. WO2005019205; 2005
   Google Scholar
• Merck & Co. WO2005019206; 2005
   Google Scholar
• Merck & Co. WO2006101780; 2006
   Google Scholar
• Merck & Co. WO2005018547; 2005
   Google Scholar
• Merck & Co. WO2006007501; 2006
   Google Scholar
• Kyowa Hakko/Fuji Film. WO2005035512; 2005
   Google Scholar
• Kyowa Hakko/Fuji Film. JP2005232016; 2005
   Google Scholar
• Merck & Co. WO2006031348; 2006
   Google Scholar
• Array Biopharma. WO2006044825; 2006
   Google Scholar
• Merck & Co. WO2006023440; 2006
   Google Scholar
• Merck & Co. WO2004112699; 2004
   Google Scholar
• Merck & Co. WO2005018638; 2005
   Google Scholar
• Merck & Co. WO2006086358; 2006
   Google Scholar
• Merck & Co. WO2006007491; 2006
   Google Scholar
• Merck & Co. WO2006023083; 2006
   Google Scholar
• Garbaccio RM, Tasber ES, Neilson LA, et al. Kinesin spindle protein (KSP) inhibitors. Part 7: design and synthesis of 3,3-disubstituted dihydropyrazolobenzoxazines as potent inhibitors of the mitotic kinesin KSP. Bioorg Med Chem Lett 2007;17:5671-6
   PubMed Web of Science ®Google Scholar
• Roecker AJ, Coleman PJ, Mercer SP, et al. Kinesin spindle protein (KSP) inhibitors. Part 8: design and synthesis of 1,4-diaryl-4,5-dihydropyrazoles as potent inhibitors of the mitotic kinesin KSP. Bioorg Med Chem Lett 2007;17:5677-82
   PubMed Web of Science ®Google Scholar
• Merck & Co. WO2006068933; 2006
   Google Scholar
• Merck & Co. WO2004111193; 2004
   Google Scholar
• Merck & Co. WO2006007497; 2006
   Google Scholar
• Tarby CM, Kaltenbach III RF, Huynh T, et al. Inhibitors of human mitotic kinesin Eg5: characterization of the 4-phenyl-tetrahydroisoquinoline lead series. Bioorg Med Chem Lett 2006;16:2095-100
   PubMed Web of Science ®Google Scholar
• GSK/Cytokinetics. WO2005060692; 2005
   Google Scholar
• GSK. WO2005062847; 2005
   Google Scholar
• GSK/Cytokinetics. WO2006020358; 2006
   Google Scholar
• Parrish CA, Adams ND, Auger KR, et al. Novel ATP-competitive kinesin spindle protein inhibitors. J Med Chem 2007;50:4939-52
   PubMed Web of Science ®Google Scholar
• Jackson JR, Auger KR, Gilmartin AG, et al. A resistance mechanism for the KSP inhibitor ispinesib implicates point mutations in the compound binding site. Mol Targets Cancer Ther 2005:[Abstract C207]
   Google Scholar
• GSK. WO2006113432; 2006
   Google Scholar
• Merck KGaA. WO2005063735; 2005
   Google Scholar
• Merck KGaA. WO2007054138; 2007
   Google Scholar
• Merck KGaA. WO2006133805; 2006
   Google Scholar
• Merck KGaA. WO2006002726; 2006
   Google Scholar
• Merck KGaA. WO2006133821; 2006
   Google Scholar
• Altana. WO2006018435; 2006
   Google Scholar
• Nycomed. WO2007096393; 2007
   Google Scholar
• Nycomed. WO2007096395; 2007
   Google Scholar
• Chiron. WO2005070930; 2005
   Google Scholar
• Schering. WO2006098961; 2006
   Google Scholar
• Schering. WO2006098962; 2006
   Google Scholar
• Kalypsys. WO2007011721; 2007
   Google Scholar
• Kalypsys. WO2007011760; 2007
   Google Scholar
• Kalypsys. WO2007011759; 2007
   Google Scholar
• Kalypsys. WO2007011647; 2007
   Google Scholar
• Pinkerton AB, Lee TT, Hoffman TZ, et al. Synthesis and SAR of thiophene containing kinesin spindle protein (KSP) inhibitors. Bioorg Med Chem Lett 2007;17:3562-9
   PubMed Web of Science ®Google Scholar
• Ogo N, Oishi S, Matsuno K, et al. Synthesis and biological evaluation of L-cysteine derivatives as mitotic kinesin Eg5 inhibitors. Bioorg Med Chem Lett 2007;17:3921-4
   PubMed Web of Science ®Google Scholar
• Skoufias DA, Debonis S, Saoudi Y, et al. S-Trityl-L-cysteine is a reversible, tight binding inhibitor of the human kinesin Eg5 that specifically blocks mitotic progression. J Biol Chem 2006;281:17559-69
   PubMed Web of Science ®Google Scholar
• Merck KGaA. WO2006094602; 2006
   Google Scholar
• Okumura H, Nakazawa J, Tsuganezawa K, et al. Phenothiazine and carbazole-related compounds inhibit mitotic kinesin Eg5 and trigger apoptosis in transformed culture cells. Toxicol Lett 2006;166:44-52
   PubMed Web of Science ®Google Scholar
• Riken. JP2006348021; 2006
   Google Scholar
• Cytokinetics. WO2002057244; 2002
   Google Scholar
• Merck & Co. WO2004004652; 2004
   Google Scholar
• Liu F, You Q, Chen Y. Pharmacophore identification of KSP inhibitors. Bioorg Med Chem Lett 2007;17:722-6
   PubMed Web of Science ®Google Scholar
• Jiang C, Chen Y, Wang X, You Q. Docking studies on kinesin spindle protein inhibitors: an important cooperative ‘minor binding pocket’ which increases the binding affinity significantly. J Mol Model 2007;13:987-92
   PubMed Web of Science ®Google Scholar
• Cytokinetics. WO2005107762; 2005
   Google Scholar
• Cytokinetics. WO2007056056; 2007
   Google Scholar
• Cytokinetics. WO2007056143; 2007
   Google Scholar
• Cytokinetics. WO2007056078; 2007
   Google Scholar
• Johnson RK, Mccabe FL, Caulder E, et al. SB-715992, a potent and selective inhibitor of the mitotic kinesin KSP, demonstrates broad-spectrum activity in advanced murine tumors and human tumor xenografts. Proc Am Assoc Cancer Res 2002;43:[Abstract 1335]
   Google Scholar
• Chu QS, Holen KD, Rowinsky EK, et al. Phase I trial of novel kinesin spindle protein (KSP) inhibitor SB-715992 IV Q 21 days. Proc Am Soc Clin Oncol 2004;23:[Abstract 2078]
   Google Scholar
• Williams D, Kathman S, Chu Q, et al. A phase I study of SB-715992, a novel kinesin spindle protein (KSP) inhibitor: pharmacokinetic (PK)/pharmacodynamic (PD) modelling of absolute neutrophil counts (ANC). Eur J Cancer Suppl 2004;2:[Abstract 55]
   Google Scholar
• Burris HA, Lorusso P, Jones S, et al. Phase I trial of novel kinesin spindle protein (KSP) inhibitor SB-715992 IV days 1, 8, 15 q 28 days. Proc Am Soc Clin Oncol 2004;23:[Abstract 2004]
   Google Scholar
• Study of ispinesib in subjects with breast cancer (NCT00089973). ClinicalTrials.gov. 18 August 2004. Available at: http://clinicaltrials.gov/ct2/show/NCT00089973?id=NCT00089973&rank=1 [Last accessed 14 November 2007]
   Google Scholar
• Ispinesib in subjects with platinum-taxane-refractory or resistant relapsed ovarian cancer (NCT00097409). ClinicalTrials.gov. 23 November 2004. Available at: http://clinicaltrials.gov/ct2/show/NCT00097409?id=NCT00097409&rank=1 [Last accessed 14 November 2007]
   Google Scholar
• Ispinesib in patients with advanced or metastatic non-small cell lung cancer (NCT00085813). ClinicalTrials.gov. 14 June 2004. Available at: accessed] http://clinicaltrials.gov/ct2/show/NCT00085813?id=NCT00085813&rank=1 [Last accessed 14 November 2007]
   Google Scholar
• SB-715992 in treating patients with recurrent or metastatic head and neck cancer (NCT00095628). ClinicalTrials.gov. 5 November 2004. Available at: http://clinicaltrials.gov/ct2/show/NCT00095628?id=NCT00095628&rank=1 [Last accessed 14 November 2007]
   Google Scholar
• SB-715992 in treating patients with acute leukemia, chronic myelogenous leukemia, or advanced myelodysplastic syndromes (NCT00098826). ClinicalTrials.gov. 8 December 2004. Available at: http://clinicaltrials.gov/ct2/show/NCT00098826?id=NCT00098826&rank=1 [Last accessed 14 November 2007]
   Google Scholar
• Lee CW, Bélanger K, Rao SC, et al. A phase II study of ispinesib (SB-715992) in patients with metastatic or recurrent malignant melanoma: a National Cancer Institute of Canada Clinical Trials Group trial. Invest New Drugs 2007; published online 26 October 2007, doi:10.1007/s10637-007-9097-9
   Google Scholar
• Cytokinetics announces the initiation of Phase I/II clinical trial for SB-743921. Cytokinetics press release. 17 April 2006. Available at: http://www.cytokinetics.com/cyto/pr_1145284422 [Last accessed 14 November 2007]
   Google Scholar
• Woessner RD, Corrette C, Allen S, et al. ARRY-520, a KSP inhibitor with efficacy and pharmacodynamic activity in animal models of solid tumors. Proc Am Assoc Cancer Res 2007;48:[Abstract 1433]
   Google Scholar
• Lemieux C, Dewolf W, Voegtli W, et al. ARRY-520, a novel, highly selective KSP inhibitor with potent anti-proliferative activity. Proc Am Assoc Cancer Res 2007;48:[Abstract 5590]
   Google Scholar
• GARBER K. Divide and conquer: new generation of drugs targets mitosis. J Natl Cancer Inst 2005;97:874-6
   PubMedGoogle Scholar
• Marcus AI, Peters U, Thomas SL, et al. Mitotic kinesin inhibitors induce mitotic arrest and cell death in taxol-resistant and -sensitive cancer cells. J Biol Chem 2005;280:11569-77
   PubMed Web of Science ®Google Scholar
• Kapoor TM, Mayer TU, Coughlin ML, Mitchison TJ. Probing spindle assembly mechanisms with monastrol, a small molecule inhibitor of the mitotic kinesin, Eg5. J Cell Biol 2000;150:975-88
   PubMed Web of Science ®Google Scholar
• Aoki S, Ohta K, Yamazaki T, et al. Mammalian mitotic centromere-associated kinesin (MCAK). FEBS J 2005;272:2132-40
   PubMed Web of Science ®Google Scholar
• Cytokinetics. WO2004026226; 2004
   Google Scholar
• Max-Planck Institute. WO2006079478; 2006
   Google Scholar